Prosper: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled, Efficacy And Safety Study Of Enzalutamide In Patients With Nonmetastatic Castration-resistant Prostate Cancer

Trial Profile

Prosper: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled, Efficacy And Safety Study Of Enzalutamide In Patients With Nonmetastatic Castration-resistant Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2018

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PROSPER
  • Sponsors Medivation; Pfizer
  • Most Recent Events

    • 16 Mar 2018 According to an European Medicines Agency media release, additional data will be presented at the upcoming 2018 European Association of Urology.
    • 16 Mar 2018 According to an European Medicines Agency media release, Dr Cora N. Sternberg is a key investigator in this trial .
    • 16 Mar 2018 According to an European Medicines Agency media release, the European Medicines Agency (EMA) has validated and started the review process for the companys application for a Type II Variation for enzalutamide to extend the overall indication to include patients with non-metastatic castration-resistant prostate cancer (CRPC) based on results from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top